Loading...
aTyr Pharma, Inc.
ATYR•NASDAQ
Healthcare
Biotechnology
$5.83
$0.28(4.95%)
aTyr Pharma, Inc. (ATYR) AI-Powered Stock Analysis
See how aTyr Pharma, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimeraTyr Pharma, Inc. (ATYR) Stock Overall Grade
aTyr Pharma, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B+
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to aTyr Pharma, Inc.'s overall stock rating.
Forecast
C+Score
58/100Financial Growth
AScore
80/100Fundamental Growth
CScore
44/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
B+Score
75/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
B+Score
75/100aTyr Pharma, Inc. (ATYR) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 58/100 (C+), reflecting weak confidence in its potential. Financial Growth (80/100, A) and Fundamental Growth (44/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (75/100,B+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each aTyr Pharma, Inc. stock grade, including financials, comparisons, and forecasts.